TY - JOUR
T1 - Molecular profiling of intrahepatic cholangiocarcinoma
T2 - the search for new therapeutic targets
AU - Oliveira, Douglas V N P
AU - Zhang, Shanshan
AU - Chen, Xin
AU - Calvisi, Diego F
AU - Andersen, Jesper B
PY - 2017/4/3
Y1 - 2017/4/3
N2 - INTRODUCTION: Intrahepatic cholangiocarcinoma (iCCA) is the second most frequent primary tumor of the liver and a highly lethal disease. Therapeutic options for advanced iCCA are limited and ineffective due to the largely incomplete understanding of the molecular pathogenesis of this deadly tumor. Areas covered: The present review article outlines the main studies and resulting discoveries on the molecular profiling of iCCA, with a special emphasis on the different techniques used for this purpose, the diagnostic and prognostic markers identified, as well as the genes and pathways that could be potentially targeted with innovative therapies. Expert commentary: Molecular profiling has led to the identification of distinct iCCA subtypes, characterized by peculiar genetic alterations and transcriptomic features. Targeted therapies against some of the identified genes are ongoing and hold great promise to improve the prognosis of iCCA patients.
AB - INTRODUCTION: Intrahepatic cholangiocarcinoma (iCCA) is the second most frequent primary tumor of the liver and a highly lethal disease. Therapeutic options for advanced iCCA are limited and ineffective due to the largely incomplete understanding of the molecular pathogenesis of this deadly tumor. Areas covered: The present review article outlines the main studies and resulting discoveries on the molecular profiling of iCCA, with a special emphasis on the different techniques used for this purpose, the diagnostic and prognostic markers identified, as well as the genes and pathways that could be potentially targeted with innovative therapies. Expert commentary: Molecular profiling has led to the identification of distinct iCCA subtypes, characterized by peculiar genetic alterations and transcriptomic features. Targeted therapies against some of the identified genes are ongoing and hold great promise to improve the prognosis of iCCA patients.
U2 - 10.1080/17474124.2017.1292127
DO - 10.1080/17474124.2017.1292127
M3 - Review
C2 - 28162004
SN - 1747-4124
VL - 11
SP - 349
EP - 356
JO - Expert Review of Gastroenterology & Hepatology
JF - Expert Review of Gastroenterology & Hepatology
IS - 4
ER -